IPP Bureau

Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division

By IPP Bureau - March 13, 2023

The company will be submitting the responses to US FDA observations within stipulated timeline

Zydus receives final approval from the USFDA for Olanzapine
Zydus receives final approval from the USFDA for Olanzapine

By IPP Bureau - March 13, 2023

Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions

Agilent announces digital pathology workflow solution
Agilent announces digital pathology workflow solution

By IPP Bureau - March 13, 2023

Open, scalable, end-to-end solution to improve diagnostic quality and efficiency

Keytruda + chemotherapy improved overall survival versus chemotherapy alone as for advanced malignant pleural mesothelioma
Keytruda + chemotherapy improved overall survival versus chemotherapy alone as for advanced malignant pleural mesothelioma

By IPP Bureau - March 12, 2023

For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma

Marksans Pharma announces USFDA approval for Famotidine Tablets
Marksans Pharma announces USFDA approval for Famotidine Tablets

By IPP Bureau - March 11, 2023

Marksans' OTC Famotidine Tablets USP are acid reducers

USFDA completes inspection of Lupin’s Vizag facility
USFDA completes inspection of Lupin’s Vizag facility

By IPP Bureau - March 11, 2023

The inspection concluded with no observations

Baxter launches the 'Choose Freedom' campaign for kidney disease patients
Baxter launches the 'Choose Freedom' campaign for kidney disease patients

By IPP Bureau - March 11, 2023

Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.

Build a sustainable healthcare and lifesciences industry, say Experts
Build a sustainable healthcare and lifesciences industry, say Experts

By IPP Bureau - March 11, 2023

Time to combine innovation, access and technology to deliver positive patient outcomes

IIT Kanpur and Reliance Life Sciences join forces to revolutionize gene therapy for hereditary eye diseases
IIT Kanpur and Reliance Life Sciences join forces to revolutionize gene therapy for hereditary eye diseases

By IPP Bureau - March 11, 2023

IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases

Bachem raises $116 million through capital increase
Bachem raises $116 million through capital increase

By IPP Bureau - March 11, 2023

Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies

NATCO launches additional strengths for generic version of Revlimid in USA
NATCO launches additional strengths for generic version of Revlimid in USA

By IPP Bureau - March 10, 2023

Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Glenmark and Cediprof inks exclusive distribution agreement in US
Glenmark and Cediprof inks exclusive distribution agreement in US

By IPP Bureau - March 10, 2023

The agreement is for USFDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

Zydus receives final approval from the USFDA for Erythromycin Tablets
Zydus receives final approval from the USFDA for Erythromycin Tablets

By IPP Bureau - March 10, 2023

Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body

Alembic receives USFDA tentative approval for Brexpiprazole Tablets
Alembic receives USFDA tentative approval for Brexpiprazole Tablets

By IPP Bureau - March 10, 2023

Clariant launches Plantasens Pro LM
Clariant launches Plantasens Pro LM

By IPP Bureau - March 10, 2023

Plantasens Pro LM is 100% natural, readily biodegradable, COSMOS and Natrue certified

Latest Stories

Interviews

Packaging